Larsen P R, Atkinson A J, Wellman H N, Goldsmith R E
J Clin Invest. 1970 Jun;49(6):1266-79. doi: 10.1172/JCI106339.
The effect of 5,5'-diphenylhydantoin on thyroxine metabolism was examined in five normal volunteers. Intravenous injection of radiothyroxine was followed by a 10-12 day control and subsequent 9-14 day treatment periods. During oral administration of diphenylhydantoin, plasma thyroxine concentration decreased to about 80% of its pretreatment level and the plasma radiothyroxine disappearance rate increased a maximum of 20% over control estimates. These changes were a result of increases in both urinary and fecal excretion of radioisotope.A minimum plasma thyroxine was apparent after 10-12 days of diphenylhydantoin administration. In two of the subjects, treatment was sufficiently prolonged to achieve this new steady state. In these subjects, the decrease in total body thyroxine was balanced by the increase in the fractional turnover rate. As a result, absolute thyroxine degradation during diphenylhydantoin administration was unchanged from the pretreatment values. Plasma ultrafiltration was used to estimate the free thyroxine fraction at regular intervals during the control and treatment periods. During diphenylhydantoin treatment, there was little or no change in this fraction and therefore, absolute free thyroxine decreased. Thyroxine-binding globulin and thyroxine-binding prealbumin capacities remained constant. These results indicate that thyroxine degradation can proceed at a normal rate in subjects receiving diphenylhydantoin despite decreases in plasma free thyroxine concentration. If free thyroxine is the only portion of the hormone available for cellular utilization, then free thyroxine clearance must be increased in these subjects. This increase in clearance could represent either a direct stimulation of peripheral thyroxine metabolism by diphenylhydantoin, or it could reflect the response of intrinsic regulatory systems to a diphenylhydantoin-mediated displacement of thyroxine from thyroxine-binding globulin. Whatever the mechanism for this effect, a decreased free thyroxine value in patients receiving diphenylhydantoin may not imply hypothyroidism.
在五名正常志愿者身上研究了5,5'-二苯基乙内酰脲对甲状腺素代谢的影响。静脉注射放射性甲状腺素后,先有10 - 12天的对照期,随后是9 - 14天的治疗期。在口服二苯基乙内酰脲期间,血浆甲状腺素浓度降至治疗前水平的约80%,血浆放射性甲状腺素消失率比对照估计值最高增加20%。这些变化是放射性同位素尿排泄和粪排泄增加的结果。服用二苯基乙内酰脲10 - 12天后出现最低血浆甲状腺素水平。在两名受试者中,治疗时间足够长以达到这种新的稳态。在这些受试者中,全身甲状腺素的减少被分数周转率的增加所平衡。因此,服用二苯基乙内酰脲期间甲状腺素的绝对降解与治疗前值相比没有变化。在对照期和治疗期定期使用血浆超滤来估计游离甲状腺素分数。在二苯基乙内酰脲治疗期间,该分数几乎没有变化或没有变化,因此绝对游离甲状腺素减少。甲状腺素结合球蛋白和甲状腺素结合前白蛋白容量保持恒定。这些结果表明,尽管血浆游离甲状腺素浓度降低,但在接受二苯基乙内酰脲的受试者中甲状腺素降解仍可正常进行。如果游离甲状腺素是该激素可用于细胞利用的唯一部分,那么在这些受试者中游离甲状腺素清除率必须增加。清除率的这种增加可能代表二苯基乙内酰脲对周围甲状腺素代谢的直接刺激,或者它可能反映内在调节系统对二苯基乙内酰脲介导的甲状腺素从甲状腺素结合球蛋白上的置换的反应。无论这种作用的机制如何,接受二苯基乙内酰脲的患者游离甲状腺素值降低可能并不意味着甲状腺功能减退。